Skip to main content

Table 3 CR rates between DNMT3A R882 mutation and wild type patients after one or two cycles of induction based on different regimen

From: Influence of DNMT3A R882 mutations on AML prognosis determined by the allele ratio in Chinese patients

Induction cycles

Anthracyclines

Total

CR/n (%)

R882 wild-type

CR/n (%)

R882 mutation

CR/n (%)

OR (95% CI)

P value

First cycle

Aclarubicin

95/187 (50.80)

92/173 (53.18)

3/14 (21.43)

4.165 (1.122–15.451)

0.022

Daunorubicin

28/84 (33.33)

27/78 (34.62)

1/6 (16.67)

2.647 (0.294–23.821)

0.653

Idarubicin

90/203 (44.33)

83/183 (45.35)

7/20 (35.00)

1.541 (0.589–4.041)

0.376

Mitoxantrone

114/287 (39.72)

107/264 (40.53)

7/23 (30.43)

1.558 (0.620–3.915)

0.343

Pirarubicin

21/74 (28.38)

20/69 (28.99)

1/5 (20.00)

1.633 (0.172–15.524)

1.000

First or second cycle

Aclarubicin

243/379 (64.12)

229/349 (65.62)

14/30 (46.67)

2.181 (1.030–4.619)

0.038

  1. CR complete response, R882 arginine 882, OR odds ratio, CI confidence interval
  2. Italic values indicate significance of P value (P < 0.05)